NextCell Pharma AB Profit Margin

NextCell Pharma AB (NXTCL.ST) currently reports a profit margin of -440.78% as of June 2026. That compares with -398.39% in the prior-year period — down 10.6% year over year. That is below the Healthcare sector average of 9.48%. Use the charts on this page to explore NextCell Pharma AB's profit margin history and peer comparisons.

NextCell Pharma AB's profit margin decreased from -398.39% to -440.78% — a 10.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NextCell Pharma AB's profit margin of -440.78% is lower than the Healthcare sector average of 9.48%. That is roughly 4749.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but NextCell Pharma AB's current -440.78% should be judged against Healthcare norms (sector average: 9.48%) and against NXTCL.ST's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -440.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for NextCell Pharma AB, and consider following NXTCL.ST for alerts when major investors trade the stock.